Hemostasis and coagulation pathway protein

Hemostasis and coagulation pathway proteins represent a sophisticated biological system of enzymes, zymogens, and cofactors that work in concert to prevent blood loss and maintain vascular integrity. The process is characterized by a cascade of proteolytic activations, primarily involving serine proteases, which ultimately leads to the generation of thrombin and the formation of a stable fibrin clot (StatPearls, NBK470250). This pathway is a critical therapeutic focus for managing conditions such as venous thromboembolism, atrial fibrillation, and myocardial infarction, where anticoagulants like Factor Xa inhibitors or direct thrombin inhibitors are employed (PubMed, 30004367). Conversely, deficiencies in these proteins, such as Factor VIII or IX, result in hemophilia, requiring replacement therapies to restore hemostatic function (NIH, GeneReviews). The balance of this system is delicate, as pharmacological modulation carries a significant risk of life-threatening hemorrhage or paradoxical thrombosis (PubMed, 28638119). Beyond clot formation, these proteins also interact with the inflammatory and immune systems, influencing wound healing and tissue repair (PubMed, 25614230).

Other names

Coagulation cascadeBlood clotting factorsHemostatic systemCoagulation factorsHemostasis and coagulation pathway proteins

Drugs targeting this pathway act by inhibiting specific coagulation factors (e.g., Factor Xa or Thrombin), antagonizing the synthesis of vitamin K-dependent factors, or promoting the dissolution of fibrin clots through plasminogen activation.